ICMJE DISCLOSURE FORM

Date: 12/05/2023

Your Name: <u>Dr Aylén Vanessa Ospina</u>

Manuscript Title: Is there a role for first generation TKIs in adjuvant setting for EGFR mutated early NSCLC?

Manuscript number (if known): CCO-23-27

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)					
		Time frame: Since the initial	planning of the work					
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None						
		Time frame: past 36 months						
2	Grants or contracts from any entity (if not indicated in item #1 above).	None						
3	Royalties or licenses	None						
4	Consulting fees	None AstraZeneca Bristol Myers Squibb						

		Company	
		Pfizer	
		Merck	
		Takeda Oncology	
		Roche	
5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus, manuscript writing or		
educational events			
6 Payment for expert		None	
	testimony		
7	Support for attending meetings and/or travel	None	
	_	Pfizer	
		Roche	
		MSD	
		Janssen	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	None	
committee or advocacy			
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Please summarize the above conflict of interest in the following box:

Dr. Ospina reports consultant fees from AstraZeneca, Bristol Myers Squibb Company, Pfizer, Merck, Takeda Oncology and Roche; and support for attending meetings and/or travel from Pfizer, Roche, MSD and Janssen.

Please place an "X" next to the following statement to indicate your agreement	Please	place an	"X" ı	next to	the 1	following	statement	to in	dicate '	your a	greemen
--	--------	----------	-------	---------	-------	-----------	-----------	-------	----------	--------	---------

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Signed:

Ay Naw of

Dr Aylén Vanessa Ospina

ICMJE DISCLOSURE FORM

Date: 18/05/2023

Your Name: <u>Dr Mariano Provencio</u>

Manuscript Title: Is there a role for first generation TKIs in adjuvant setting for EGFR mutated early NSCLC?

Manuscript number (if known): CCO-23-27

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None AstraZeneca Bristol Myers Squibb Company	

		Eli LIlly	
		F. Hoffmann-La Roche	
		Janssen	
		Pfizer	
		MSD	
		Takeda Oncology	
		Roche	
5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
0	testimony	None	
	testimony		
7	Constant for attending	Nega	
7	Support for attending	None	
	meetings and/or travel	AstraZeneca	
		Astrazeneca	
		Boehringer Ingelheim	
		Boeininger ingemeini	
		Bristol Myers Squibb	
		Company	
		Eli LIIIy	
		F. Hoffmann-La Roche	
		Pierre Fabre	
		Pharmaceuticals	
		Takeda Oncology	
		Roche	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		+
	services		
13	Other financial or non-	None	
13	financial interests	INOTIC	
	imanciai interests		

Please summarize the above conflict of interest in the following box:

Dr. Provencio reports consultant fees AstraZeneca, Bristol Myers Squibb Company, Eli Lilly, F. Hoffmann-La Roche, Janssen, Pfizer, MSD, Takeda Oncology, Roche. He also reports support for attending meetings and/or travel from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb Company, Eli Lilly, F. Hoffmann-La Roche Pierre Fabre Pharmaceuticals, Takeda Oncology, Roche.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Dr Mariano Provencio